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BACKGROUND: Activating mutation of KRAS and BRAF are focused on as potential prognostic and predictive biomarkers in patients with
colorectal cancer (CRC) treated with anti-EGFR therapies. This study investigated the clinicopathological features and prognostic
impact of KRAS/BRAF mutation in advanced and recurrent CRC patients.
METHOD: Patients with advanced and recurrent CRC treated with systemic chemotherapy (n¼229) were analysed for KRAS/BRAF
genotypes by cycleave PCR. Prognostic factors associated with survival were identified by univariate and multivariate analyses using
the Cox proportional hazards model.
RESULTS: KRAS and BRAF mutations were present in 34.5% and 6.5% of patients, respectively. BRAF mutated tumours were more likely
to develop on the right of the colon, and to be of the poorly differentiated adenocarcinoma or mucinous carcinoma, and peritoneal
metastasis. The median overall survival (OS) for BRAF mutation-positive and KRAS 13 mutation-positive patients was 11.0 and 27.7
months, respectively, which was significantly worse than that for patients with wild-type (wt) KRAS and BRAF (40.6 months)
(BRAF; HR¼4.25, Po0.001, KRAS13; HR¼2.03, P¼0.024). After adjustment for significant features by multivariate Cox regression
analysis, BRAF mutation was associated with poor OS (HR¼4.23, P¼0.019).
CONCLUSION: Presence of mutated BRAF is one of the most powerful prognostic factors for advanced and recurrent CRC.
The KRAS13 mutation showed a trend towards poor OS in patients with advanced and recurrent CRC.
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Although the epidermal growth factor receptor (EGFR) has
important roles in cell differentiation and proliferation in normal
cells, activation of EGFR signalling is frequently observed in
colorectal cancer (CRC) cells, resulting in cell proliferation,
migration and metastasis, evasion of apoptosis, or angiogenesis
(Fang and Richardson, 2005). Indeed, B35% of CRC tissues
carry a mutation in codons 12 or 13 of KRAS that leads to the
constitutive activation of downstream pathways, including the Ras/
Raf/MAP/MEK/ERK and/or PTEN/PI3K/Akt pathways (Kinzler
and Vogelstein, 1999; Wan et al, 2004; Benvenuti et al, 2007;
Di Nicolantonio et al, 2008; Souglakos et al, 2009). BRAF is a
downstream molecule of KRAS. Although more than 40 somatic
mutations in the BRAF kinase domain have been described, the
most common mutation across various cancers is the classic
GTG-GAG substitution at the position 1799 of exon 15, which
results in the V600E amino acid change, and the subsequent
constitutive activation of the EGFR signalling pathway. Recent
studies from Western countries have suggested that BRAF
mutations occur in 10–20% of patients with sporadic disease
(Jass, 2007; Benvenuti et al, 2007; Di Nicolantonio et al, 2008;
Souglakos et al, 2009; Farin ˜a-Sarasqueta et al, 2010), whereas other
reports have revealed that tumours harbouring BRAF mutations
have different clinical and histopathological features compared
with tumours that harbour KRAS mutations (Kim et al, 2006; Deng
et al, 2008; Zlobec et al, 2010). However, the frequency and
clinicopathological features of KRAS/BRAF mutation in Japanese
CRC patients remain unknown.
Information on KRAS/BRAF genotype is extremely useful in
systemic chemotherapy for advanced and recurrent CRC patients,
not just for predicting the therapeutic efficiency of anti-EGFR
therapy, but also for identifying patients with poor prognoses.
Therefore, both KRAS and BRAF are currently being focused on as
potential prognostic and predictive biomarkers in patients with
metastatic disease treated with anti-EGFR therapies, such as
panitumumab and cetuximab (Karapetis et al, 2008; Bokemeyer
et al, 2009; Tol et al, 2009; Van Cutsem et al, 2009). A number of
retrospective analyses have revealed that patients with KRAS
mutations do not benefit from cetuximab treatment, suggesting
that KRAS genotype is a useful predictive marker for cetuximab
therapy in CRC (Karapetis et al, 2008; Bokemeyer et al, 2009; Van
Cutsem et al, 2009). It has also been reported that wild-type (wt)
BRAF is required for a successful response to panitumumab
or cetuximab therapies in metastatic CRC (Di Nicolantonio et al,
2008; Laurent-Puig et al, 2009; Souglakos et al, 2009; De Roock
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set al, 2010). In contrast, the prognostic relevance of KRAS
genotype in CRC has been controversial despite a number of
multi-institutional investigations dating from the 1990s (Andreyev
et al, 1998; French et al, 2008; Kakar et al, 2008; Ogino et al, 2009;
Roth et al, 2010). Although few studies have investigated the
impact of KRAS12 and KRAS13 mutations on CRC prognosis, a
series of recent studies have highlighted the potential adverse
prognostic impact of BRAF mutations, using both patients with
stage II and III disease and patients across all disease stages (Ogino
et al, 2009; Farin ˜a-Sarasqueta et al, 2010). Although Tol et al
(2009) analysed BRAF genotypes in 520 metastatic CRC patients,
all the patients were treated with chemotherapy plus bevacizumab
with or without cetuximab. Furthermore, BRAF genotypes were
analysed in a large subgroup of 845 metastatic CRC treated with
FOLFIRI and FOLFOX chemotherapy with or without cetuximab
as the first-line treatment in the CRYSTAL and OPUS studies,
respectively (Bokemeyer et al, 2010). Thus, although the prog-
nostic value of BRAF has been analysed in CRC patients treated
with specific chemotherapy regimens, it remains unclear what
impact the KRAS12, KRAS13, and BRAF mutations have on clinical
outcomes of all patients with advanced or recurrent CRC treated
with systemic treatments.
We have previously introduced the cycleave PCR technique as
applicable to the routine screening of KRAS/BRAF mutations in
CRC from pathological specimens, such as surgical and biopsy
specimens (Yokota et al, 2010). Cycleave PCR utilises chimeric
DNA-RNA-DNA probes labelled with a fluorescent dye and
quencher, and the accuracy of cycleave PCR in detecting KRAS/
BRAF mutations has been confirmed by assessment of the
concordance between cycleave PCR and reverse transcriptase
PCR-coupled direct sequencing (Yatabe et al, 2006; Yokota et al,
2010).
The aim of this study was to evaluate the KRAS/BRAF genotypes
of advanced and recurrent CRC patients and to assess the effects of
these genotypes on clinical outcome. To this end, we analysed the
frequencies of the KRAS12, KRAS13 and BRAF mutations, and
correlated these results with the clinicopathological features of 229
Japanese CRC patients.
PATIENTS AND METHODS
Patients and tissues
Analysis of the genes encoding KRAS and BRAF was performed on
surgically resected or biopsied specimens from CRC patients at
our institution from 2002 to 2010. Hematoxylin and eosin (H and
E)-stained slides were retrospectively collected and histologic
subtypes were reviewed by an experienced gastrointestinal
pathologist. Clinicopathological and survival analyses were sub-
sequently performed on all patients with advanced and recurrent
CRC who underwent systemic chemotherapy. Clinical data,
including patient age at diagnosis, tumour location, and metastatic
sites, were retrieved from patient records. Right-sided cancers
included tumours from the caecum to transverse colon, left-sided
included tumours from the splenic flexure to the rectosigmoid
junction. Specimens used for KRAS/BRAF genotyping were either
frozen or paraffin embedded tissues. For the KRAS/BRAF
genotyping, appropriate approvals were obtained from the
institutional review committee and written informed consent was
obtained from all patients.
DNA extraction
DNA was extracted from surgical or biopsy specimens. Briefly,
tumour cell-rich areas in H and E-stained sections were marked
under a microscope, and tissues scratched from the same areas
were sequentially deparaffinised and unstained. Recovered tissues
were incubated in 1X PCR buffer containing 100mgml
 1
proteinase K for 1h at 541C. After heat inactivation at 951C for
3min, samples were used directly as template DNA for PCR assay.
KRAS/BRAF genotyping by cycleave PCR
To detect point mutations at KRAS codons 12, 13 and 61, we used
the cycleave PCR technique (Yatabe et al, 2006; Sakamoto et al,
2007; Yokota et al, 2010). Each chimeric DNA-RNA-DNA probe
was labelled with a fluorescent dye and quencher at each end that
targeted the G12D, G12V, G12R, G12C, G12S, or G12A mutations
in codon 12, the G13D or G13C mutations in codon 13, or the
G61H, G61L, G61E, or G61K mutations in codon 61 of KRAS.
We also designed probes that targeted the V600E mutation in
BRAF. The PCR reactions were performed using a cycleave PCR
core kit (TAKARA, Co. Ltd, Ohtsu, Japan). Fluorescent signals
were quantified using the Smart Cycler system (SC-100; Cepheid,
Sunnyvale, CA, USA).
Statistical analysis
The w
2, Fischer’s exact tests and Student’s t-tests were used to
analyse the relationship between variables using SYSTAT software
(SYSTAT Software Inc., Richmond, CA, USA). The KRAS wt/BRAF
wt (wild/wild), KRAS12 mutant (G12X), KRAS13 mutant (G13X),
and BRAF mutant (V600E) groups were analysed separately.
Overall survival (OS) was calculated from the starting date of the
first-line chemotherapy until death from any cause, or censored at
last follow-up visit. Survival data were analysed using the Kaplan–
Meier product-limit method. Comparison of survival curves was
carried out using the log-rank test. We first performed a univariate
comparison of survival functions for factors that could potentially
affect the survival time using the log-rank test, and then a
multivariate analysis using the Cox proportional hazards model.
P-values o0.05 were considered statistically significant, and all
P-values represent two-sided significance tests.
RESULTS
Frequency of KRAS and BRAF gene mutations in CRC
patients
According to our previous investigation on the spectrum of KRAS
genotypes in our database of CRC cases, the most frequent
mutations at KRAS codon 12 were the G12D, G12V, G12R, G12C,
G12S and G12A mutations, which accounted for more than 95% of
the codon 12 mutations. Similarly, the G13D and G13C mutations
at codon 13, and the G61H, G61L, G61E, and G61K mutations at
codon 61 were also found to be the most common at each site
(Yokota et al, 2010). All the KRAS mutations we located have been
previously described as oncogenically active and were present in
the COSMIC (catalogue of somatic mutations in cancer) database
(Sanger Institute, Cambridge, UK). Therefore, a series of specific
probes targeting the common mutations in KRAS codons 12, 13
and 61 were designed for subsequent analysis of KRAS mutation
frequency in our population of CRC patients. Because the most
common mutation in BRAF is a valine to glutamate transition at
position 600 of the protein (V600E), we designed probes targeting
the V600E mutation in BRAF.
We initially analysed the KRAS genotypes of 349 CRC patients at
our institution for which pathological specimens were available
by cycleave PCR. The KRAS mutations were present in 35.7%
(n¼126) of patients tested, including 24.4% (n¼86) that
exhibited codon 12 mutations and 11.3% (n¼40) that exhibited
codon 13 mutations. However, only 4.7% (n¼15) of the patients
tested were positive for the BRAF V600E mutation (n¼319). None
of the KRAS-mutated samples carried a concomitant BRAF
mutation. Approximately 2–3% of the surgical specimens could
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snot be evaluated by cycleave PCR, probably due to over-fixation by
formalin, as we reported previously (Yokota et al, 2010).
For the subsequent clinicopathological and survival analysis, we
picked out 229 patients with advanced and recurrent CRC for
which we could access complete clinicopathological information.
The KRAS mutations were present in 34.5% (n¼79) of advanced
and recurrent CRC patients, including 23.1% (n¼53) with codon
12 mutations and 11.4% (n¼26) with codon 13 mutations. The
BRAF mutation was found in 6.6% (n¼15) of this population
(Table 1).
Association of BRAF/KRAS mutations with
clinicopathological features
We then correlated the KRAS and BRAF genotypes with
clinicopathological features of CRC, including primary tumour
location, histological findings, and sites of metastases. We
categorised the population into four subtypes; those with wt KRAS
and BRAF (wild/wild), KRAS12 mutations (G12X), KRAS13
mutations (G13X), and BRAF mutations (V600E).
For disease status, recurrent disease was more frequent in the
KRAS12 and KRAS13 mutant groups than in the wild/wild group.
There was no association between KRAS/BRAF genotype and age,
gender or PS. Primary tumours were located at the rectum
in almost half of the wild/wild and G12X populations. However,
right-side tumour location was more frequent (60%) in patients
with BRAF mutation in all subtypes (P¼0.0391) (Table 2).
Furthermore, 46.2% (12 out of 26) of the primary tumours with
KRAS13 mutations were located on the right side whereas the
frequencies of right-side location were 20.7% (28 out of 135) and
26.4% (14 out of 53), for the wild/wild and G12X groups,
respectively (Table 2). The BRAF and KRAS13 mutations were
present in 14.3% (9 out of 63) and 19.0% (17 out of 63) of right-
sided CRC, respectively. These results suggested that the BRAF and
KRAS codon 13 mutations were associated with a right-sided
tumour location.
Analysis with respect to histology showed that the frequencies of
poorly differentiated adenocarcinoma (por), mucinous carcinoma
(muc) and signet-ring cell carcinoma (sig) were o10.9% in
patients with wt BRAF, which supported previous reports that such
histologies are rare in CRC (Ogino et al, 2006; Catalano et al, 2009).
However, 60.0% (9 out of 15) of CRC cases with BRAF mutation
were of the por or muc subtypes, although no signet-ring cell
carcinomas were observed. The BRAF mutations were present in
36.0% (9 out of 25) of patients with por/muc histology.
Furthermore, 60.0% (9 out of 15) of CRCs with BRAF mutation
metastasised to the peritoneum, compared with B15% of CRCs
with other subtypes (P¼0.0062) (Table 2). However, Fisher’s exact
test indicated no statistically significant correlation between
tumour histology and peritoneal metastasis in BRAF mutant
patients. No other significant differences or trends in metastatic
patterns with respect to KRAS/BRAF genotypes were observed.
Details of the first line chemotherapy regimens used are shown
in Table 2. In all, 66.4% of patients were treated with oxaliplatin-
based regimens, 14.4% with irinotecan-based regimens, and 19.2%
with fluoropyrimidine-based chemotherapy without oxaliplatin or
irinotecan. There were no significant differences in treatment
regimens between KRAS/BRAF genotypes. A total of 86 (63.7%)
patients with wild/wild tumours and five (33.3%) patients with
BRAF mutation-positive tumours received anti-EGFR therapy,
whereas few patients with KRAS12 or KRAS13 mutations received
anti-EGFR therapy (1.9% and 3.8%, respectively).
Survival
The median OS for BRAF mutation-positive patients was 11.0
months, which was significantly worse than for patients with wt
KRAS and BRAF (40.6 months) (HR¼4.25, 95% CI 2.08–8.67,
Po0.001; Figure 1). The median OS for all KRAS mutation-
positive patients, including those with KRAS12 or KRAS13
mutations, was not statistically different to that of wt KRAS and
BRAF patients (HR¼1.51, 95% CI 0.97–2.36, P¼0.071). However,
if OS for KRAS13 mutation-positive patients was analysed
separately from KRAS12 mutation-positive patients, then the
median OS for KRAS13 mutation-positive patients was signifi-
cantly worse than that for wt KRAS and BRAF patients
(27.7 months vs 40.6 months, HR¼2.03, 95% CI 1.10–3.74,
P¼0.024; Figure 1). In contrast, the median OS for KRAS12
mutation-positive patients was 38.8 months, similar to that for wt
KRAS and BRAF patients (HR¼1.28, 95% CI 0.74–2.19, P¼0.376;
Figure 1). Univariate analysis showed that two other variables were
also significantly associated with poor survival, PS ECOGX2 and
gender (Table 3). KRAS13 mutation was not statistically associated
with poor survival by univariate analysis. This was because we
compared OS for KRAS13 mutation-positive patients with that for
wt KRAS13 patients, which included KRAS12 and BRAF mutation-
positive patients as well as wt KRAS and BRAF patients. The
por/sig/muc histology and lung metastasis showed a trend towards
poor OS (P¼0.066 and P¼0.061, respectively).
To correct for significant prognostic factors, a Cox proportional
hazards model that included age, gender, PS, KRAS status, BRAF
status, pathological finding, number of metastasis and metastatic
sites, was used. As two variables, WBC and ALP, had missing data,
they were not included in the multivariate analysis. BRAF mutation
and PS ECOGX2 were confirmed as poor prognostic factors.
Specifically, the relative risk of death for patients with BRAF
mutation was 4.23 (95% CI 1.76–10.2) compared with patients with
wt BRAF tumours (P¼0.001) (Table 3). Multivariate analysis also
found that por/sig/muc histology, age465, and liver metastasis
were negative independent prognostic factors. However, KRAS13
mutation was not found to be an independent prognostic factor.
DISCUSSION
In this study, we examined the incidence of KRAS and BRAF
mutations in advanced and recurrent CRC patients, and clarified
the relationship between KRAS/BRAF genotypes and clinicopatho-
logical features, including survival. Up to now, estimates of KRAS
gene mutation frequency in metastatic CRCs have been based on
selective clinical studies or drug admission trials with variable
inclusion criteria. To our knowledge, the present report is the first
to provide data on the frequency and type of KRAS/BRAF
mutations from a large Japanese population of advanced and
recurrent CRC patients tested in a routine setting.
Our results showed that KRAS mutation was observed in around
35% of CRC cases, which included 25% of patients with mutations
at codon 12 and 10% of patients with mutations at codon 13. This
observation agreed well with previous studies on selected cohorts
that reported frequencies in the range of 30–42% (Table 1).
The cycleave PCR technique was simultaneously applied to the
detection of BRAF mutation, thought to be an adverse prognostic
marker as well as a predictive marker for anti-EGFR therapy.
Our analysis demonstrated that the BRAF V600E mutation was
observed in B5% of CRC patients, which appeared to be lower
Table 1 Spectrum of KRAS/BRAF mutations in CRC
KRAS
BRAF Wild type G12 G13 61
Wild type 135 53 26 0
V600E 15 0 0 0
Abbreviation: CRC¼colorectal cancer. n¼229.
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sthan that previously reported from Western countries. None of the
CRC patients in our study carried both KRAS and BRAF mutations,
supporting the hypothesis that KRAS and BRAF mutations occur
in a mutually exclusive manner (Rajagopalan et al, 2002; Frattini
et al, 2004; Ahlquist et al, 2008). One possible explanation for the
comparatively low frequency of BRAF mutation might be the
Table 2 Association of BRAF and KRAS mutational status with clinicopathological features in colorectal cancer
KRAS/BRAF status Wild/wild KRAS mutant BRAF mutant
Clinicopathological features n¼135
G12X
n¼53
G13X
n¼26
Total (G12X+G13X)
n¼79
V600E
n¼15 *P-value
Overall
n¼229
Age at diagnosis (median) 62 (27–83) 62 (40–85) 68 (41–79) 63 (40–85) 62 (30–80)
Gender
Female 47 (34.8%) 27 (50.9%) 13 (50.0%) 40 (50.6%) 8 (53.3%) 0.1082 95
Male 88 (65.2%) 26 (49.1%) 13 (50.0%) 39 (49.4%) 7 (46.7%) 134
ECOG PS
0–1 115 (85.2%) 46 (86.8%) 22 (84.6%) 68 (86.1%) 13 (86.7%) 0.7898 196
42 9 (6.7%) 4 (7.5%) 3 (11.5%) 7 (8.9%) 2 (13.3%) 18
Unknown 11 (8.1%) 3 (5.7%) 1 (3.8%) 4 (5.1%) 0 (0.0%) 15
Tumour location
Right sided 28 (20.7%) 14 (26.4%) 12 (46.2%) 26 (32.9%) 9 (60.0%) 0.0391 63
Left sided 41 (30.4%) 13 (24.5%) 3 (11.5%) 16 (20.3%) 3 (20.0%) 60
Rectum 64 (47.4%) 25 (47.2%) 11 (42.3%) 36 (45.6%) 3 (20.0%) 103
Other 2 (1.5%) 1 (1.9%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 3
Disease status
Advanced 82 (60.7%) 26 (49.1%) 11 (42.3%) 37 (46.8%) 9 (60.0%) 0.2269 128
Recurrence 53 (39.3%) 27 (50.9 %) 15 (57.7%) 42 (53.2%) 6 (40.0%) 101
Histological subtype
Well 28 (20.7%) 8 (15.1%) 7 (26.9%) 15 (19.0%) 1 (6.7%) o0.0001 44
Mod 91 (67.4%) 37 (69.8%) 18 (69.2%) 55 (69.6%) 5 (33.3%) 151
por/sig/muc 10 (7.4%) 5 (9.4%) 1 (3.8%) 6 (7.6%) 9 (60.0%) 25
Other 1 (0.7%) 0 (0.0%) 0 (0.0%) 0 (0%) 0 (0.0%) 1
Unknown 5 (3.7%) 3 (5.7%) 0 (0.0%) 3 (3.8%) 0 (0.0%) 8
Metastatic sites
Liver 90 (66.7%) 31 (58.5%) 15 (57.7 %) 46 (58.2%) 10 (66.7%) 0.6595 146
Peritoneum 30 (22.2%) 11 (20.8%) 4 (15.4%) 15 (20.0%) 9 (60.0%) 0.0062 54
Lung 42 (31.1%) 21 (39.6%) 10 (38.5%) 31 (39.2%) 5 (33.3%) 0.6867 78
CNS 1 (0.7%) 0 (0.0%) 1 (3.8%) 1 (1.3%) 0 (0.0%) 0.3503 2
Bone 9 (6.7%) 3 (5.7%) 2 (7.7%) 5 (6.3%) 2 (13.3%) 0.7736 16
Number of metastatic sites
42 64 (47.4%) 23 (43.4%) 14 (53.8%) 37 (46.8%) 10 (66.7%) 0.4078 111
o1 71 (52.6%) 30 (56.6%) 12 (46.2%) 42 (53.2%) 5 (33.3%) 118
WBC
WBC410000 9 (6.7%) 4 (7.5%) 2 (7.7%) 6 (7.6%) 0 (0.0%) 0.7622 15
WNL 100 (74.1%) 38 (71.7%) 20 (76.9%) 58 (73.4%) 14 (93.3%) 172
Unknown 26 (19.3%) 11 (20.8%) 4 (15.4%) 15 (20.2%) 1 (6.7%) 42
ALP
ALP4300 59 (43.7%) 18 (34.0%) 12 (46.2%) 30 (38.0%) 6 (40.0%) 0.6635 95
WNL 49 (36.3%) 24 (45.3%) 10 (38.5%) 34 (43.0%) 8 (53.3%) 91
Unknown 27 (20.0%) 11 (20.8%) 4 (15.4%) 15 (20.0%) 1 (6.7%) 43
First-line regimen
IRI-based 24 (17.8%) 6 (11.3%) 2 (7.7%) 8 (10.1%) 1 (6.7%) 0.4062 33
OXA-based 85 (63.0%) 37 (69.8%) 17 (65.4%) 54 (68.4%) 13 (86.7%) 152
Others 26 (19.3%) 10 (18.9%) 7 (26.9%) 17 (21.5%) 1 (6.7%) 44
Anti-EGFR treatment
Yes 86 (63.7%) 1 (1.9%) 1 (3.8%) 2 (2.5%) 5 (33.3%) o0.0001 93
No 44 (32.6%) 52 (98.1%) 25 (96.2%) 77 (97.5%) 10 (66.7%) 131
Unknown 5 (3.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 5
Abbreviations: CNS¼central nervous system; ECOG¼Eastern Cooperative Oncology Group; EGFR¼epidermal growth factor receptor; PS¼performance status; well¼well-
differentiated adenocarcinoma; mod¼moderately differentiated adenocarcinoma; por¼poorly differentiated adenocarcinoma; muc¼mucinous carcinoma; sig¼signet-ring cell
carcinoma; CNS¼central nervous system; IRI¼irinotecan; OXA¼oxaliplatin, ALP¼alkaline phosphatase; WNL¼within normal range; WBC¼white blood cells. Patients with
both wild-type KRAS and wild-type BRAF were designated as wild/wild. All patients with KRAS mutations (n¼79) either in codon 12 (G12X) or in codon 13 (G13X) are shown
as total (G12X+G13X). *P-values calculated between wild-type KRAS and BRAF (wild/wild), KRAS12 mutant (G12X), KRAS13 mutant (G13X), and BRAF mutant (V600E) groups.
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sdifferent ethnic group. Indeed, several studies have reported that
the mutation rates of DNA mismatch repair (MMR) genes, such as
hMSH2 and hMLH1, in hereditary non-polyposis colorectal cancer,
is variable between countries. Therefore, geographical variation
may account for differences in the mutation spectrum of BRAF,a s
observed for MMR genes (Wei et al, 2003; Lee et al, 2005; Goldberg
et al, 2008).
We also investigated the clinicopathological characteristics of
CRC patients with respect to KRAS12, KRAS13 and BRAF
mutations. In accordance with previous reports (Kim et al, 2006;
Deng et al, 2008; Zlobec et al, 2010), BRAF mutation occurred
more frequently in right-sided tumour locations. We also found
that 60.0% of the BRAF mutation-positive specimens were of the
poorly differentiated adenocarcinoma or mucinous carcinoma
subtypes. It was recently reported that mucinous histology predicts
a poor response to oxaliplatin- and/or irinotecan-based chemo-
therapies and is correlated with poor OS (Catalano et al, 2009). As
BRAF mutation was more frequent in mucinous groups than non-
mucinous carcinoma, as demonstrated by the present study and
others (Ogino et al, 2006), the poor prognosis associated with
mucinous histology may be at least partially explained by BRAF
gene mutation. These specific clinicopathological features support
the hypothesis that the BRAF mutation-mediated carcinogenesis in
CRC is initiated by altered BRAF function as an early step in the
serrated pathway (Bennecke et al, 2010), leading to activation
of RAF-MEK-ERK-MAP signalling.
In contrast to BRAF mutation, no significant differences in
clinicopathological parameters were observed according to KRAS
genotype. However, our analysis did suggest that KRAS13
mutations were also associated with right-sided tumour location.
This result raises the possibility that KRAS13 may have a distinct
phenotype from that of other KRAS genotypes.
Using a representative cohort of 229 sporadic CRCs, we
identified the BRAF V600E mutation as an independent prognostic
factor for survival in patients with advanced and recurrent CRC.
The presence of the BRAF mutation is associated with a
significantly higher risk of dying of cancer-related causes,
independently of other factors such as age, gender, PS, KRAS
status, pathological finding, number of metastasis and metastatic
sites, in agreement with other recent studies (Ogino et al, 2009; Tol
et al, 2009; Bokemeyer et al, 2010; Farin ˜a-Sarasqueta et al, 2010).
For example, analysis of stage II and stage III CRC patients
(Farin ˜a-Sarasqueta et al, 2010) was consistent with the finding that
44% of our population included recurrent disease. The BRAF
mutation was correlated with survival in a heterogeneous group of
CRC patients that included all disease stages (Ogino et al, 2009).
Furthermore, a positive correlation between BRAF mutation and
shorter survival was demonstrated in a homogeneous group of
metastatic CRC patients treated with a specific chemotherapy
regimen with or without cetuximab (Tol et al, 2009; Bokemeyer
et al, 2010). However, our study focused on the advanced
and recurrent group who received systemic chemotherapy,
including fluoropyrimidines, in combination with oxaliplatin,
irinotecan, bevacizumab and anti-EGFR antibody in several lines.
Even though all of the patients in our study received systemic
chemotherapy, a positive correlation between BRAF mutation
and shorter survival was still demonstrated, independent of
treatment arm.
The prognostic value of KRAS mutations in CRC remains
controversial, even though KRAS mutations have been associated
with a poor response to anti-EGFR antibody therapy in metastatic
CRC (Karapetis et al, 2008; Bokemeyer et al, 2009; Van Cutsem
et al, 2009). Despite a number of studies investigating a prognostic
role for KRAS mutations, no definitive conclusions can be drawn
(Castagnola and Giaretti, 2005). This may be due to differences
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Figure 1 Kaplan–Meier plot showing overall survival in metastatic and
recurrent colon cancer patients according to KRAS and BRAF V600E
mutational status (n¼229). mut, mutated.
Table 3 Factors associated with overall survival in univariate and multivariate analyses
Univariate analysis Multivariate analysis
Variable
Hazard ratio
(95% CI) P-value
Hazard ratio
(95% CI) P-value
Age 465 0.74 (0.48–1.13) 0.157 0.55 (0.34–0.90) 0.018
Female 1.59 (1.06–2.37) 0.025 1.35 (0.85–2.12) 0.201
PS (ECOG)X2 6.14 (3.15–12.0) o0.001 7.66 (3.68–16.0) o0.001
BRAF mutant 3.78 (1.89–7.54) o0.001 4.23 (1.76–10.2) 0.001
KRAS 12 mutant 1.03 (0.62–1.74) 0.897 1.57 (0.88–2.81) 0.128
KRAS 13 mutant 1.67 (0.93–3.02) 0.086 1.51 (0.76–2.98) 0.239
Pathology, por/sig/muc 1.74 (0.96–3.14) 0.066 2.38 (1.16–4.90) 0.018
Number of metastasis X2 0.93 (0.63–1.40) 0.738 1.12 (0.61–2.05) 0.714
Liver metastasis 1.36 (0.88–2.11) 0.162 1.72 (1.02–2.90) 0.042
Lung metastasis 0.66 (0.42–1.02) 0.061 0.59 (0.32–1.11) 0.100
Peritoneal metastasis 1.21 (0.76–1.93) 0.417 1.56 (0.85–2.88) 0.154
WBC X10000 1.27 (0.51–3.15) 0.605 — —
ALP X300 1.21 (0.78–1.88) 0.395 — —
Anti-EGFR treatment 0.80 (0.53–1.20) 0.277 — —
Abbreviations: ALP¼alkaline phosphatase; PS¼performance status; ECOG¼Eastern Cooperative Oncology Group; EGFR¼epidermal growth factor receptor; por¼poorly
differentiated adenocarcinoma; muc¼mucinous carcinoma; sig¼signet-ring cell carcinoma; CI¼confidence interval; WBC¼white blood cells.
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sbetween the studies in terms of study size, patient selection,
tumour sampling, use of archival versus fresh/frozen material, or
laboratory methods and data analyses. More importantly, few
studies have differentiated KRAS mutations at codon 12 from those
at codon 13 with respect to clinicopathological features and
survival (Bazan et al, 2002). Our analysis revealed that mutation at
KRAS12 had no effect on patient OS. In contrast, our Kaplan–
Meier curves clearly demonstrated that OS for patients with
KRAS13 mutations were significantly worse than for those who had
wt KRAS and BRAF. It has been reported that stage III patients
with KRAS mutations displayed significantly worse disease-free
survival, as compared with those with wt KRAS (Farin ˜a-Sarasqueta
et al, 2010). This finding may be partially explained by the impact
of KRAS13 mutations on prognosis. As both univariate and
multivariate analysis failed to confirm KRAS13 mutation as an
independent prognostic factor, the prognostic value of mutations
at KRAS13 remains unclear in advanced and recurrent CRC.
In non-small-cell lung cancer there are differences in transforming
potential and EGFR tyrosine kinase inhibitor sensitivity associated
with EGFR somatic mutations L858R and deletion mutant Del
(746-750) (Carey et al, 2006). Therefore, it remains a possibility
that the different KRAS mutations at codons 12 and 13 may
have different biological consequences that could influence the
prognosis for CRC.
With respect to technical issue on KRAS and BRAF genotyping,
we evaluated the prognostic value of the mutations frequently
found in KRAS and BRAF using specific PCR probes. In contrast,
direct sequencing is able to detect all possible KRAS and BRAF
mutations including some more rare mutations. In fact, it is
reported that KRAS codon 146 mutation, which was identified by
direct sequencing, was associated with resistance to cetuximab
plus irinotecan therapy although this is a minor oncogenic KRAS
mutation (Loupakis et al, 2009). Therefore, direct sequencing may
be able to obtain further insights into predictive and prognostic
impact of these mutations.
Our study found that the median OS of patients with wt BRAF
was generally longer than that observed in other reports. It could
be argued that the selection of patients with good prognosis could
bias the results in this study. Indeed, more than half of our study
population was screened for KRAS/BRAF genotype to determine
the use of anti-EGFR antibody, and 42% of the patients were
treated with cetuximab combined therapy mostly as a second- or
third-line chemotherapy. Although treatment selection may be a
major reason for the longer survival observed in the present study
as compared with previous studies involving metastatic CRC
patients, univariate analysis revealed no significant differences in
survival between patients with and without anti-EGFR therapy
(38.8 months vs 32.6 months, P¼0.277) (Table 3). Furthermore,
almost all recurrent and advanced CRC patients are routinely
screened for KRAS/BRAF genotype at the initiation of the first line
chemotherapy in our institution since the use of cetuximab was
approved for the treatment of CRC patients in Japan.
Another key point of discussion is the potential treatment bias
in this retrospective analysis. The focus of the present study is the
patient group with advanced and recurrent CRC who received
systemic chemotherapy. However, we need to take the difference
in the specific treatment regimen among four genotypes into
consideration. In particular, 63.7% (86 out of 135) of wt KRAS and
BRAF patients have received anti-EGFR therapy whereas 33.3% (6
out of 15) and 2.5% (2 out of 79) of patients with BRAF and
KRAS12/13 mutations have received anti-EGFR therapy, respec-
tively. Therefore, the prognostic advantage of wt KRAS and BRAF
patients over BRAF or KRAS13 mutation might be partially
explained by the presence of anti-EGFR therapy. Nevertheless, it is
noteworthy that the prognosis of wt KRAS and BRAF patients was
similar to that of the patients with KRAS12 mutation despite the
frequent use of anti-EGFR therapy.
In conclusion, our retrospective analysis demonstrated that
BRAF mutation was an independent prognostic factor in advanced
and recurrent CRC. Although the presence of KRAS12 mutation
had no apparent effect on OS in advanced and recurrent disease,
the prognostic value of KRAS13 mutation remains uncertain. Our
results are useful not only for predicting the efficacy of anti-EGFR
therapy, but also for identifying patients with shorter OS in
response to systemic chemotherapy, regardless of the use of anti-
EGFR therapy. The exact effects of KRAS12 and KRAS13 mutations
on survival require further study. The application of novel
strategies targeting BRAF kinase is warranted for the treatment
of CRC patients with BRAF mutation.
ACKNOWLEDGEMENTS
We thank Motoko Nimura and Akiko Yoshinari for their excellent
technical assistance with the molecular genetic experiments.
REFERENCES
Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, Lind GE,
Dallapiccola B, Lothe RA (2008) RAS signaling in colorectal carcinomas
through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia 10:
680–686, 2 p following 686
Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998)
Kirsten ras mutations in patients with colorectal cancer: the multicenter
‘RASCAL’ study. J Natl Cancer Inst 90: 675–684
Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA,
La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino RM,
Labianca R, Gebbia N, Russo A (2002) Specific codon 13 K-ras mutations
are predictive of clinical outcome in colorectal cancer patients, whereas
codon 12 K-ras mutations are associated with mucinous histotype.
Ann Oncol 13: 1438–1446
Bennecke M, Kriegl L, Bajbouj M, Retzlaff K, Robine S, Jung A, Arkan MC,
Kirchner T, Greten FR (2010) Ink4a/Arf and oncogene-induced
senescence prevent tumor progression during alternative colorectal
tumorigenesis. Cancer Cell 18: 135–146
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M,
Veronese S, Siena S, Bardelli A (2007) Oncogenic activation of the
RAS/RAF signaling pathway impairs the response of metastatic colo-
rectal cancers to anti-epidermal growth factor receptor antibody
therapies. Cancer Res 67: 2643–2648
Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J,
de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A,
Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic colorectal
cancer. J Clin Oncol 27: 663–671
Bokemeyer C, Ko ¨hne CH, Rougier P, Stroh C, Schlichting M, Van Cutsem E
(2010) Cetuximab with chemotherapy (CT) as first-line treatment
for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL
and OPUS studies according to KRAS and BRAF mutation status. ASCO
Annual Meeting, Abstract No. 3506. J Clin Oncol 28: 15S
Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F,
Haley JD, Gibson N, Sliwkowski MX (2006) Kinetic analysis of epidermal
growth factor receptor somatic mutant proteins shows increased
sensitivity to the epidermal growth factor receptor tyrosine kinase
inhibitor, erlotinib. Cancer Res 66: 8163–8171
Castagnola P, Giaretti W (2005) Mutant KRAS, chromosomal
instability and prognosis in colorectal cancer. Biochim Biophys Acta
1756: 115–125
Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D,
Fornaro L, Baldelli AM, Giordani P, Rossi D, Alessandroni P, Giustini L,
Silva RR, Falcone A, D’Emidio S, Fedeli SL (2009) Mucinous histology
predicts for poor response rate and overall survival of patients with
BRAF mutation as prognostic factor in CRC
T Yokota et al
861
British Journal of Cancer (2011) 104(5), 856–862 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
scolorectal cancer and treated with first-line oxaliplatin- and/or
irinotecan-based chemotherapy. Br J Cancer 100: 881–887
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G,
Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca
F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M,
Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S,
Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO,
Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E,
Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010) Effects of
KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab
plus chemotherapy in chemotherapy-refractory metastatic colorectal
cancer: a retrospective consortium analysis. Lancet Oncol 11: 753–762
Deng G, Kakar S, Tanaka H, Matsuzaki K, Miura S, Sleisenger MH, Kim YS
(2008) Proximal and distal colorectal cancers show distinct gene-specific
methylation profiles and clinical and molecular characteristics.
Eur J Cancer 44: 1290–1301
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S,
Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A
(2008) Wild-type BRAF is required for response to panitumumab or
cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705–5712
Fang JY, Richardson BC (2005) The MAPK signalling pathways and
colorectal cancer. Lancet Oncol 6: 322–327
Farin ˜a-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ,
Lemmens VE, Rutten HJ, van den Brule AJ (2010) The BRAF V600E
mutation is an independent prognostic factor for survival in stage II and
stage III colon cancer patients. Ann Oncol 21: 2396–2402
Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, Radice P, Costa A,
Daidone MG, Leo E, Pilotti S, Bertario L, Pierotti MA (2004) Different
genetic features associated with colon and rectal carcinogenesis.
Clin Cancer Res 10: 4015–4021
French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R,
Shepherd L, Windschitl HE, Thibodeau SN (2008) Prognostic
significance of defective mismatch repair and BRAF V600E in patients
with colon cancer. Clin Cancer Res 14: 3408–3415
Goldberg Y, Porat RM, Kedar I, Shochat C, Sagi M, Eilat A, Mendelson S,
Hamburger T, Nissan A, Hubert A, Kadouri L, Pikarski E, Lerer I,
Abeliovich D, Bercovich D, Peretz T (2008) Mutation spectrum in
HNPCC in the Israeli population. Fam Cancer 7: 309–317
Jass JR (2007) Classification of colorectal cancer based on correlation
of clinical, morphological and molecular features. Histopathology 50:
113–130
Kakar S, Deng G, Sahai V, Matsuzaki K, Tanaka H, Miura S, Kim YS, (2008)
Clinicopathologic characteristics, CpG island methylator phenotype, and
BRAF mutations in microsatellite-stable colorectal cancers without
chromosomal instability. Arch Pathol Lab Med 132: 958–964
Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D,
Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ,
Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras
mutations and benefit from cetuximab in advanced colorectal cancer.
N Engl J Med 359: 1757–1765
Kim IJ, Kang HC, Jang SG, Kim K, Ahn SA, Yoon HJ, Yoon SN, Park JG
(2006) Oligonucleotide microarray analysis of distinct gene expression
patterns in colorectal cancer tissues harboring BRAF and K-ras
mutations. Carcinogenesis 27: 392–404
Kinzler KW, Vogelstein B (1999) Colorectal tumors. In: Kinzler KW,
Vogelstein B, editors. The Genetic Basis of Human Cancer. McGraw-Hill:
London, UK, pp 565–587
Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier
P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouche ´ O,
Reid J, Stone S, Penault-Llorca F (2009) Analysis of PTEN, BRAF, and
EGFR status in determining benefit from cetuximab therapy in wild-type
KRAS metastatic colon cancer. J Clin Oncol 27: 5924–5930
Lee SC, Guo JY, Lim R, Soo R, Koay E, Salto-Tellez M, Leong A, Goh BC
(2005) Clinical and molecular characteristics of hereditary non-polyposis
colorectal cancer families in Southeast Asia. Clin Genet 68: 137–145
Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D,
Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio
N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A,
Graziano F (2009) KRAS codon 61, 146 and BRAF mutations
predict resistance to cetuximab plus irinotecan in KRAS codon 12 and
13 wild-type metastatic colorectal cancer. Br J Cancer 101: 715–721
O g i n oS ,B r a h m a n d a mM ,C a n t o rM ,C l a r kJ W ,R y a nD P ,K u l k eM H ,E n z i n g e r
PC, Wolpin BM, Loda M, Fuchs CS (2006) Distinct molecular features of
colorectal carcinoma with signet ring cell component and colorectal
carcinoma with mucinous component. Mod Pathol 19: 59–68
Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M,
Giovannucci EL, Fuchs CS (2009) CpG island methylator phenotype,
microsatellite instability, BRAF mutation and clinical outcome in colon
cancer. Gut 58: 90–96
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B,
Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and
mismatch-repair status. Nature 418: 934
Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D,
Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L,
Labianca R, Cunningham D, Van Cutsem E, Bosman F (2010) Prognostic
role of KRAS and BRAF in stage II and III resected colon cancer: results
of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00
trial. J Clin Oncol 28: 466–474
Sakamoto H, Shimizu J, Horio Y, Ueda R, Takahashi T, Mitsudomi T, Yatabe Y
(2007) Disproportionate representation of KRAS gene mutation in atypical
adenomatous hyperplasia, but even distribution of EGFR gene mutation
from preinvasive to invasive adenocarcinomas. JP a t h o l212: 287–294
Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J,
Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z,
Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA (2009)
Prognostic and predictive value of common mutations for treatment
response and survival in patients with metastatic colorectal cancer.
Br J Cancer 101: 465–472
Tol J, Nagtegaal ID, Punt CJ (2009) BRAF mutation in metastatic colorectal
cancer. N Engl J Med 361: 98–99
Van Cutsem E, Ko ¨hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A,
D’Haens G, Pinte ´r T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P,
Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab
and chemotherapy as initial treatment for metastatic colorectal cancer.
N Engl J Med 360: 1408–1417
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM,
Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R, Cancer
Genome Project (2004) Mechanism of activation of the RAF-ERK
signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855–867
Wei SC, Yu CY, Tsai-Wu JJ, Su YN, Sheu JC, Wu CH, Wang CY, Wong JM
(2003) Low mutation rate of hMSH2 and hMLH1 in Taiwanese hereditary
non-polyposis colorectal cancer. Clin Genet 64: 243–251
Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T (2006) A
rapid, sensitive assay to detect EGFR mutation in small biopsy specimens
from lung cancer. J Mol Diagn 8: 335–341
Yokota T, Shibata N, Ura T, Takahari D, Shitara K, Muro K, Yatabe Y
(2010) Cycleave polymerase chain reaction method is practically
applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
(KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF)
genotyping in colorectal cancer. Transl Res 156: 98–105
Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A (2010) Clinicopatho-
logical and protein characterization of BRAF- and K-RAS-mutated
colorectal cancer and implications for prognosis. Int J Cancer 127:
367–380
BRAF mutation as prognostic factor in CRC
T Yokota et al
862
British Journal of Cancer (2011) 104(5), 856–862 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s